BioAsset

Insights / All articles

Industry Trends

Designer-ish Babies: Will it be the Future?

By Jingqiu Tian, Research Analyst at BioAsset · 7 slides

There has been an unprecedented increase in the number of startups offering genetic screening services for IVF embryos. Nucleus Genomics is one example of a company selling these services.

These startups do not only screen for diseases such as breast cancer and diabetes. They also screen for more controversial traits, including height, hair color and IQ. The predictions come from technologies such as whole-genome sequencing and gene association studies, which generate trait predictions from an embryo’s gene sequences.

The results need careful interpretation. Most traits involve many genes, few have proven causal links, and much of what these tests produce reflects statistical probability rather than certainty.

The applications of this screening technology have drawn countless arguments, especially concerns about morality once traits like height and IQ are involved. The future of designer-ish babies remains uncertain: the screening startups keep growing, while many countries maintain much stricter regulations on the technology.

This article is the text version of a BioAsset slide post. See the original slides on bioasset.info.